Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs
Open Access
- 4 July 2011
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (4) , 549-555
Abstract
We report the first randomized study comparing early hospital discharge with standard hospital-based follow-up after high-dose chemotherapy (HDCT) and PBSCT. Patients aged 18–65 years, with an indication of PBSCT for non-leukemic malignant diseases were randomly assigned between two arms. Arm A consisted of early hospital discharge (HDCT during hospitalization, discharge at day 0, home stay with a caregiver, outpatient clinic follow-up). In arm B patients were followed up as inpatients. In total 131 patients were analyzed (66 in arm A and 65 in arm B). Patient characteristics and hematological reconstitution were comparable between the two groups. In arm A, 26 patients were actually discharged early. Patients in group A spent fewer days in hospital (11 vs 12 days, P=0.006). This strategy resulted in a 6% mean cost reduction per patient when compared with the conventional hospital-based group. The early discharge approach within the French health system, while safe and feasible, is highly dependent on social criteria (caregiver availability and home to hospital distance). It is almost always associated with conventional hospital readmission during the aplasia phase, and limits cost savings when considering the whole population of patients benefiting from HDCT in routine clinical practice.Keywords
This publication has 20 references indexed in Scilit:
- Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological diseaseLeukemia & Lymphoma, 2009
- Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic MalignanciesJournal of Clinical Oncology, 2006
- Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphomaAnnals of Hematology, 2006
- Outpatient-based peripheral blood stem cell transplantation for patients with multiple myelomaThe Hematology Journal, 2004
- Lack of caregivers limits use of outpatient hematopoietic stem cell transplant programBone Marrow Transplantation, 2002
- Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin’s lymphoma: results from the University of Nebraska Medical Center 1989 to 1995Bone Marrow Transplantation, 1999
- Feasibility and cost-effectiveness of outpatient autotransplants in multiple myelomaBone Marrow Transplantation, 1997
- High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approachBone Marrow Transplantation, 1997
- Peripheral Blood Progenitor Cell Transplantation: Clinical, Practical, and Economic ConsiderationsJournal of Hematotherapy, 1994
- The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myelomaEuropean Journal of Cancer, 1994